Triple Therapy for Acute Deep Thrombophlebitis

RuDusky, Basil M.
June 1980
Angiology;Jun1980, Vol. 31 Issue 6, p398
Academic Journal
Therapy for patients with extensive thrombophlebitis is often inadequate with available methods. The reluctance of most physicians in private practice to use streptokinase or urokinase is understandable when one considers the cost, hospitalization, length of stay and risks involved. This article discusses a unique and previously unreported mode of drug therapy in these patients, consisting of combination of drugs designed to combine the antithrombotic and thrombus-antipropagating effects of warfarin, the anti-inflammatory effect of trypsin-chymotrypsin enzymes, and the antiplatelet aggregating, antiadhesion, and possible enhanced fibrinolytic effects of aspirin with added buffered protection Ascriptin A/D). This treatment program has been a safe, efficient, economical, and highly effective one for a very costly, common, and disabling disease. It therefore fulfills the ideal criteria for any form of therapy, provided one is knowledgable of its content, and adheres to its contraindications as well as to the basic application of the drugs involved. It is hoped that further investigations along these lines will continue until an ideal solution is reached. Although this is a preliminary report, this study will continue in its present form, and will be expanded to include a series of patients on the aspirin-enzyme combination without the use of warfarin.


Related Articles

  • DISCUSSION. Perler, Bruce // Vascular Surgery;Jan/Feb2000, Vol. 34 Issue 1, p23 

    Focuses on the management of primary axillosubclavian venous thrombosis. Medical comorbidity experienced by patients with secondary upper extremity venous thrombosis; Use of surgical thrombectomy to prevent recurrent venous thrombosis; Safety and efficacy of urokinase compared to streptokinase...

  • THROMBOLYTIC TREATMENT OF VENOUS THROMBOEMBOLISM. Gurewich, Victor // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p341 

    Describes the thrombolytic treatment for deep venous thromboembolism. Objective of thrombolytic therapy; Pharmacologic efficacy of streptokinase and urokinase; Diagnostic procedure for venous thromboembolism.

  • THROMBOLYSIS AS AN ALTERNATIVE TO PULMONARY EMBOLECTOMY. Porter, John M. // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p373 

    Discusses the potential application of thrombolysis as an alternative to pulmonary embolectomy. Incidence and acute survival statistics of pulmonary embolism; Role of heparin in the treatment of pulmonary embolism; Evaluation of streptokinase and urokinase as thrombolytic agents.

  • Thrombolytic Therapy: Agents, Indication, Clinical Performance, and Side Effects. Tilsner, V.; Greul, W. // Vascular Surgery;Mar/Apr1979, Vol. 13 Issue 2, p79 

    Thrombolytic therapy is successful in 70% of fresh occlusions and in over 40% of chronic occlusions. Vascular surgery is often superior to thrombolytic therapy on the arterial side, but inferior on the venous side. Streptokinase acts faster and is considerably cheaper than urokinase, but it...

  • The Use of Thrombolytic Agents: Choice of Patient, Drug Administration, Laboratory Monitoring. Marder, Victor J. // Annals of Internal Medicine;May79, Vol. 90 Issue 5, p802 

    Presents information on a study which examined the aspects of treatment faced by the practitioner or specialist who must decide if a patient's illness warrants thrombolytic therapy. Properties of Streptokinase and urokinase; Patient selection; Principles of thrombolytic therapy.

  • North Baden venous lysis trial (NBVL): multicentre prospective randomized phlebographically controlled trial on the effect of ultra-high versus conventional doses of streptokinase in fresh leg—pelvis venous thromboses. Heinrich, F.; Heinrich, U. // Vascular Medicine;1998, Vol. 3 Issue 2, p87 

    Since no previous randomized comparison has been carried out between ultra-high and conventional dosage streptokinase therapy of fresh venous thromboses, the NBVL trial was carried out as a prospective, randomized, multicentre, phlebographically monitored comparison of the results and adverse...

  • Thrombophilic defects not associated with increased risk for recurrent VTE during warfarin therapy.  // Hem/Onc Today;1/10/2009, Vol. 10 Issue 1, p31 

    The article presents findings of a study on the association between thrombophilic defects and risk for recurrent venous thromboembolism (VTE) during warfarin therapy.

  • Don't halt Coumadin, taper it? H.D.B. // Cortlandt Forum;09/25/97, Vol. 10 Issue 9, p111 

    Reports on concern over the cessation of Coumadin (warfarin) and the recurrences of deep venous thrombosis (DVT). Prolonging prothrombin time; Effect of Coumadin lasting for days after it is stopped; Optimal duration of therapy for DVT patients.

  • Cerebral Venous Thrombosis: A Guide to Diagnosis and Drug Treatment. Hsu, F.P.; Nesbit, G.M.; Kuether, T.; Barnwell, S. // CNS Drugs;2000, Vol. 14 Issue 6, p425 

    Cerebral venous thrombosis (CVT) is a relatively rare pathological condition. The clinical presentations can be nonspecific and quite variable, frequently resulting in delayed or missed diagnosis. The symptoms include headache, nausea, vomiting, visual disturbance, altered consciousness and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics